Company Overview and News

 
BUZZ: Genting Singapore hits 1-1/2-year low; chart suggests more downside

2018-09-18 theedgemarkets
** Shares of Genting Singapore Ltd fall as much as 1.96% to S$1.00, their lowest since March 28, 2017.
G13 GIGNF GIGNY

 
Genting first half earnings retreat

2018-08-30 thestar.com.my
Revenue and Ebitda from Resorts World Sentosa for H1’18 were comparable with that of the previous year, with growth in both the gaming and non-gaming businesses.
GMALY G13 4715 GMALF GIGNF GEBHF GIGNY

3
Foreign casino operators go all in as they vie for Osaka license

2018-08-21 theedgemarkets
OSAKA (Aug 21): In late July, a lavish fireworks display lit up Osaka’s skies in the finale to one of Japan’s most famous festivals, courtesy of a first-time sponsor: Macau casino operator Melco Resorts and Entertainment Ltd.
MGM GIGNY G13 506186 CZR GLXYENT GIGNF LVS MS

3
Foreign casino operators go all in as they vie for Osaka license

2018-08-20 bworldonline
OSAKA — In late July, a lavish fireworks display lit up Osaka’s skies in the finale to one of Japan’s most famous festivals, courtesy of a first-time sponsor: Macau casino operator Melco Resorts and Entertainment Ltd.
MGM GIGNY G13 506186 CZR GLXYENT GIGNF LVS MS

3
Foreign casino operators go all in as they vie for Osaka licence

2018-08-20 channelnewsasia
OSAKA: In late July, a lavish fireworks display lit up Osaka's skies in the finale to one of Japan's most famous festivals, courtesy of a first-time sponsor: Macau casino operator Melco Resorts and Entertainment Ltd.
MGM GIGNY G13 506186 CZR GLXYENT GIGNF LVS MS

3
Foreign casino operators go all in as they vie for Osaka licence

2018-08-20 theedgemarkets
OSAKA (Aug 20): In late July, a lavish fireworks display lit up Osaka's skies in the finale to one of Japan's most famous festivals, courtesy of a first-time sponsor: Macau casino operator Melco Resorts and Entertainment Ltd.
MGM GIGNY G13 506186 CZR GLXYENT GIGNF LVS MS

3
Foreign casino operators go all in as they vie for Osaka license

2018-08-20 reuters
OSAKA (Reuters) - In late July, a lavish fireworks display lit up Osaka’s skies in the finale to one of Japan’s most famous festivals, courtesy of a first-time sponsor: Macau casino operator Melco Resorts and Entertainment Ltd (MLCO.O).
MGM GIGNY G13 506186 CZR GLXYENT GIGNF LVS MS

3
Foreign casino operators go all in as they vie for Osaka license

2018-08-20 channelnewsasia
OSAKA: In late July, a lavish fireworks display lit up Osaka's skies in the finale to one of Japan's most famous festivals, courtesy of a first-time sponsor: Macau casino operator Melco Resorts and Entertainment Ltd.
MGM GIGNY G13 506186 CZR GLXYENT GIGNF LVS MS

 
Genting’s S’pore unit 2Q profit in line with forecasts

2018-08-07 theedgemarkets
Genting Bhd (Aug 6, RM8.69) Retain outperform with an unchanged target price of RM11.50: Genting Singapore plc, a 52.7% subsidiary of Genting Bhd, reported a net profit of S$177.6 million (RM724.61 million) for the second quarter of financial year 2018 (2QFY18), posting a year-on-year (y-o-y) growth of 23.9%. The results were in line with our and consensus full-year forecasts for Genting Singapore.
G13 GIGNF GEBHF GIGNY

 
Affin Hwang maintains ‘buy’ call on Genting

2018-08-07 thestar.com.my
KUALA LUMPUR: Genting Singapore delivered positive first half 2018 results as its VIP segment continued to grow, gaining more market share at the expense of its competitors.
G13 GIGNF GIGNY

 
Buzz: Genting Singapore could see further declines — technicals

2018-08-06 theedgemarkets
Trend intensity indicator has formed higher lows and moved up 2 points to 18 on Monday, signalling a downtrend.
G13 GIGNF GIGNY

 
Genting Singapore cut to sell at AmInvestment Bank

2018-08-06 theedgemarkets
KUALA LUMPUR (Aug 6): AmInvestment Bank analyst Gan Huey Ling downgraded the recommendation on Genting Singapore Ltd to sell from hold.
G13 GIGNF GIGNY

1
Name-and-Shame Approach Puts More Women on Singapore Boards - Bloomberg

2018-08-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
S08 STT DBSDY DB SPXCF SPSTF GIGNY S68 SPXCY G13 D05 BLK DBSDF N2IU SPSTY GIGNF

1
Name-and-shame approach puts more women on Singapore boards

2018-07-31 malaymail
SINGAPORE, July 31 — Singapore lags most financial hubs when it comes to gender diversity on corporate boards, so much so that a government-backed group has started calling out companies with no female directors.
S08 STT DB SPSTF GIGNY G13 BLK N2IU SPSTY GIGNF

1
Name-and-shame approach puts more women on Singapore boards

2018-07-31 theedgemarkets
SINGAPORE (July 31): Singapore lags most financial hubs when it comes to gender diversity on corporate boards, so much so that a government-backed group has started calling out companies with no female directors.
S08 STT DB SPSTF GIGNY G13 BLK N2IU SPSTY GIGNF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...